

# Emanuela Zappulo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6061630/publications.pdf>

Version: 2024-02-01

56  
papers

986  
citations

394421

19  
h-index

501196

28  
g-index

57  
all docs

57  
docs citations

57  
times ranked

1538  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. <i>Antibiotics</i> , 2022, 11, 183.	3.7	16
2	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	3.6	9
3	Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, .	0.8	1
4	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103814.	2.0	2
5	Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients. <i>Clinical Epidemiology and Global Health</i> , 2022, 16, 101100.	1.9	3
6	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2078.	2.6	24
7	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to Fusobacterium periodonticum?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 625581.	3.9	59
8	Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19. <i>Infectious Diseases</i> , 2021, 53, 382-385.	2.8	23
9	Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 705948.	2.8	1
10	Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1237-1246.	2.4	3
11	Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11399.	2.6	24
12	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 261-273.	1.8	8
13	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. <i>Journal of Clinical Medicine</i> , 2020, 9, 4066.	2.4	19
14	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102282.	2.0	10
15	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 191-202.	4.4	3
16	The role of curcumin in liver diseases. <i>Archives of Medical Science</i> , 2019, 15, 1608-1620.	0.9	14
17	Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. <i>IDCases</i> , 2019, 17, e00537.	0.9	6
18	Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. <i>Medical Mycology</i> , 2019, 57, 987-996.	0.7	18

#	ARTICLE	IF	CITATIONS
19	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz445.	0.9	21
20	Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. <i>Infection</i> , 2019, 47, 59-65.	4.7	12
21	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. <i>In Vivo</i> , 2019, 33, 177-182.	1.3	16
22	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e57-e60.	1.5	6
23	Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 44-45.	2.0	13
24	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	0.8	6
25	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 173-182.	0.8	30
26	Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. <i>Infezioni in Medicina</i> , 2019, 27, 32-39.	1.1	4
27	Management of chronic viral hepatitis in the hematological patient. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 227-241.	4.4	9
28	Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. <i>In Vivo</i> , 2018, 32, 1255-1258.	1.3	1
29	Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 709-717.	2.4	55
30	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. <i>Sexual Health</i> , 2018, 15, 408.	0.9	16
31	No evidence of congenital varicella zoster virus infection assessed through dried blood spot in children with autism spectrum disorders. <i>Future Virology</i> , 2017, 12, 333-337.	1.8	0
32	Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. <i>European Journal of Internal Medicine</i> , 2017, 46, e45-e47.	2.2	16
33	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. <i>International Journal of Infectious Diseases</i> , 2017, 63, 23-29.	3.3	26
34	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
35	Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders. <i>In Vivo</i> , 2017, 31, 467-473.	1.3	16
36	Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. <i>In Vivo</i> , 2017, 31, 695-700.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 557-572.	4.1	19
38	The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1363-1377.	5.0	56
39	Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.	2.4	6
40	Beclabuvir for the treatment of hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1111-1121.	4.1	17
41	Discontinued drugs in 2012 – 2013: hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 239-251.	4.1	35
42	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 493.	2.0	29
43	Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. <i>Reviews on Recent Clinical Trials</i> , 2014, 9, 1-7.	0.8	26
44	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 763-773.	4.4	41
45	GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1179-1186.	4.4	10
46	MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 719-728.	4.1	32
47	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1211-1223.	4.1	28
48	Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 775-782.	4.4	30
49	ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. <i>Current Medicinal Chemistry</i> , 2014, 21, 3261-3270.	2.4	36
50	Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?. <i>Infezioni in Medicina</i> , 2014, 22, 11-8.	1.1	10
51	Prevalence and titre of antibodies to cytomegalovirus and epstein-barr virus in patients with autism spectrum disorder. <i>In Vivo</i> , 2014, 28, 621-6.	1.3	11
52	Exposure to Varicella Zoster Virus is higher in children with autism spectrum disorder than in healthy controls. Results from a case-control study. <i>In Vivo</i> , 2014, 28, 627-31.	1.3	7
53	Prevalence of herpes simplex virus 1 and 2 antibodies in patients with autism spectrum disorders. <i>In Vivo</i> , 2014, 28, 667-71.	1.3	8
54	Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together. <i>Medical Hypotheses</i> , 2013, 81, 26-35.	1.5	37

#	ARTICLE	IF	CITATIONS
55	Urinary polyomavirus infections in neurodevelopmental disorders. Open Journal of Psychiatry, 2013, 03, 18-25.	0.6	1
56	Prevalence of HHV-6 and HHV-8 antibodies in patients with autism spectrum disorders. In Vivo, 2013, 27, 843-9.	1.3	5